Raphael Mohr

14PUBLICATIONS
61CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)Predictive and prognostic markersCardiology (incl. cardiovascular diseases)Innate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jun 17, 2026
Lobar Yttrium-90 Radioembolization with BSA-Based Dosimetry for Unresectable Hepatocellular Carcinoma: Baseline Vascularity Predicts Responders to the Combination with Targeted Therapy or Immune Checkpoint Inhibition.

|Sep 23, 2025
HLA-A*01:01-B*08:01-C*07:01 is linked to early-onset immune checkpoint inhibitor-induced myositis and myocarditis.

Leonie Müller-Jensen, Lukas Flatz, Omar Hasan Ali

|May 03, 2025
Soluble Urokinase Plasminogen Activator Receptor Predicts Survival and Hepatic Decompensation in Advanced Hepatocellular Carcinoma.

Fabian Artusa, Sven Lamatsch, Minh Duc Phan

|Mar 19, 2025
Development of Liver-Heart Score for Early Detection of Myocardial Contractile Dysfunction in Cirrhosis by Strain Imaging.

Marcel Razpotnik, Simona Bota, Philipp Wimmer

|Jan 24, 2025
miR-223 and Chromogranin A Affect Inflammatory Immune Cell Activation in Liver Metastasis of Neuroendocrine Neoplasms.

Lukas Geisler, Katharina Detjen, Teresa Hellberg

|Nov 09, 2024
Extracellular Vesicles May Predict Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma.

Mara Egerer, Kathrin Schuch, David Schöler

Pageof 3

Frequent Collaborators

9 joint publications

Frank Tacke

2 joint publications

Felix Krenzien

2 joint publications

Alexander Wree

2 joint publications

Wolfgang Boehmerle